These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. Advani RH; Hong F; Fisher RI; Bartlett NL; Robinson KS; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Stewart DA; Gordon LI; Kahl BS; Friedberg JW; Blum KA; Habermann TM; Tuscano JM; Hoppe RT; Horning SJ J Clin Oncol; 2015 Jun; 33(17):1936-42. PubMed ID: 25897153 [TBL] [Abstract][Full Text] [Related]
9. Combined modality treatment: Outcome in patients with Hodgkin's lymphoma. Yadav BS; Sharma SC; Malhotra P; Prakash G J Cancer Res Ther; 2020; 16(1):1-6. PubMed ID: 32362601 [TBL] [Abstract][Full Text] [Related]
10. Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma? Gallamini A; Kostakoglu L Ann Oncol; 2015 Jun; 26(6):1045-1047. PubMed ID: 26003616 [No Abstract] [Full Text] [Related]
11. Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence! Borchmann P; Engert A; Diehl V Nat Rev Clin Oncol; 2011 Oct; 8(11):636-7. PubMed ID: 21971592 [No Abstract] [Full Text] [Related]
12. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. Raemaekers JM; André MP; Federico M; Girinsky T; Oumedaly R; Brusamolino E; Brice P; Fermé C; van der Maazen R; Gotti M; Bouabdallah R; Sebban CJ; Lievens Y; Re A; Stamatoullas A; Morschhauser F; Lugtenburg PJ; Abruzzese E; Olivier P; Casasnovas RO; van Imhoff G; Raveloarivahy T; Bellei M; van der Borght T; Bardet S; Versari A; Hutchings M; Meignan M; Fortpied C J Clin Oncol; 2014 Apr; 32(12):1188-94. PubMed ID: 24637998 [TBL] [Abstract][Full Text] [Related]
13. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. André MPE; Girinsky T; Federico M; Reman O; Fortpied C; Gotti M; Casasnovas O; Brice P; van der Maazen R; Re A; Edeline V; Fermé C; van Imhoff G; Merli F; Bouabdallah R; Sebban C; Specht L; Stamatoullas A; Delarue R; Fiaccadori V; Bellei M; Raveloarivahy T; Versari A; Hutchings M; Meignan M; Raemaekers J J Clin Oncol; 2017 Jun; 35(16):1786-1794. PubMed ID: 28291393 [TBL] [Abstract][Full Text] [Related]
14. Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy. Bröckelmann PJ; Müller H; Guhl T; Behringer K; Fuchs M; Moccia AA; Rank A; Soekler M; Vieler T; Pabst T; Baues C; von Tresckow B; Borchmann P; Engert A J Clin Oncol; 2021 Jan; 39(2):107-115. PubMed ID: 33058716 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of advanced Hodgkin lymphoma]. Kreissl S; Borchmann P Dtsch Med Wochenschr; 2013 Jun; 138(23):1212-4. PubMed ID: 23720173 [No Abstract] [Full Text] [Related]